View Financial HealthOctober PharmaE 配当と自社株買い配当金 基準チェック /06October PharmaE配当を支払う会社であり、現在の利回りは0.7%です。主要情報0.7%配当利回りn/aバイバック利回り総株主利回りn/a将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新Upcoming Dividend • May 21Upcoming dividend of ج.م2.50 per shareEligible shareholders must have bought the stock before 28 May 2024. Payment date: 30 May 2024. The company last paid an ordinary dividend in April 2017. The average dividend yield among industry peers is 3.3%.Upcoming Dividend • Apr 13Upcoming dividend of ج.م4.00 per shareEligible shareholders must have bought the stock before 20 April 2022. Payment date: 26 April 2022. Payout ratio is a comfortable 15% and this is well supported by cash flows. Trailing yield: 1.9%. Lower than top quartile of Egyptian dividend payers (11%). Lower than average of industry peers (4.0%).Upcoming Dividend • Jun 02Inaugural dividend of ج.م3.00 per shareEligible shareholders must have bought the stock before 09 June 2021. Payment date: 13 June 2021. The company last paid an ordinary dividend in May 2018. The average dividend yield among industry peers is 4.2%.すべての更新を表示Recent updatesNew Risk • Jun 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.7x net interest cover). Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported September 2025 fiscal period end). Market cap is less than US$100m (ج.م4.32b market cap, or US$82.7m).Board Change • May 20No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. No independent directors (9 non-independent directors). MD & Director Hesham Abdul Soliman was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.お知らせ • Apr 06October Pharma S.A.E, Annual General Meeting, Apr 27, 2026October Pharma S.A.E, Annual General Meeting, Apr 27, 2026, at 15:30 Egypt Standard Time. Location: cairo EgyptBoard Change • May 14No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. No independent directors (9 non-independent directors). Director Hesham Abdul Soliman was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.お知らせ • May 13October Pharma S.A.E, Annual General Meeting, May 31, 2025October Pharma S.A.E, Annual General Meeting, May 31, 2025, at 12:00 Egypt Standard Time. Location: cairo EgyptReported Earnings • Nov 16Third quarter 2024 earnings released: EPS: ج.م2.67 (vs ج.م4.09 in 3Q 2023)Third quarter 2024 results: EPS: ج.م2.67 (down from ج.م4.09 in 3Q 2023). Revenue: ج.م326.1m (up 24% from 3Q 2023). Net income: ج.م32.0m (down 35% from 3Q 2023). Profit margin: 9.8% (down from 19% in 3Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has increased by 23% per year, which means it is tracking significantly ahead of earnings growth.New Risk • Sep 17New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 2.7% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (2.7% operating cash flow to total debt). Minor Risks Profit margins are more than 30% lower than last year (9.9% net profit margin). Market cap is less than US$100m (ج.م1.41b market cap, or US$29.1m).Valuation Update With 7 Day Price Move • Sep 17Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ج.م117, the stock trades at a trailing P/E ratio of 9.3x. Average trailing P/E is 6x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 124% over the past three years.Reported Earnings • May 30First quarter 2024 earnings released: EPS: ج.م3.52 (vs ج.م2.94 in 1Q 2023)First quarter 2024 results: EPS: ج.م3.52 (up from ج.م2.94 in 1Q 2023). Revenue: ج.م274.4m (up 29% from 1Q 2023). Net income: ج.م50.1m (up 42% from 1Q 2023). Profit margin: 18% (up from 17% in 1Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has increased by 26% per year, which means it is tracking significantly ahead of earnings growth.Upcoming Dividend • May 21Upcoming dividend of ج.م2.50 per shareEligible shareholders must have bought the stock before 28 May 2024. Payment date: 30 May 2024. The company last paid an ordinary dividend in April 2017. The average dividend yield among industry peers is 3.3%.Reported Earnings • Mar 16Full year 2023 earnings released: EPS: ج.م12.53 (vs ج.م9.48 in FY 2022)Full year 2023 results: EPS: ج.م12.53 (up from ج.م9.48 in FY 2022). Revenue: ج.م1.01b (up 39% from FY 2022). Net income: ج.م182.1m (up 39% from FY 2022). Profit margin: 18% (in line with FY 2022). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has increased by 26% per year, which means it is tracking significantly ahead of earnings growth.New Risk • Oct 01New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (ج.م1.20b market cap, or US$38.8m).Valuation Update With 7 Day Price Move • Dec 21Investor sentiment improved over the past weekAfter last week's 19% share price gain to ج.م95.30, the stock trades at a trailing P/E ratio of 9.5x. Average trailing P/E is 5x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 210% over the past three years.Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 9 non-independent directors. Director Hesham Abdul Soliman was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 9 non-independent directors. Director Hesham Abdul Soliman was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Upcoming Dividend • Apr 13Upcoming dividend of ج.م4.00 per shareEligible shareholders must have bought the stock before 20 April 2022. Payment date: 26 April 2022. Payout ratio is a comfortable 15% and this is well supported by cash flows. Trailing yield: 1.9%. Lower than top quartile of Egyptian dividend payers (11%). Lower than average of industry peers (4.0%).Reported Earnings • Jun 19First quarter 2021 earnings releasedThe company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: ج.م165.8m (up 38% from 1Q 2020). Net income: ج.م40.6m (up 402% from 1Q 2020). Profit margin: 25% (up from 6.7% in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth.Upcoming Dividend • Jun 02Inaugural dividend of ج.م3.00 per shareEligible shareholders must have bought the stock before 09 June 2021. Payment date: 13 June 2021. The company last paid an ordinary dividend in May 2018. The average dividend yield among industry peers is 4.2%.決済の安定と成長配当データの取得安定した配当: OCPHはEG市場で注目すべき配当金を支払っていないため、支払いが安定しているかどうかを確認する必要はありません。増加する配当: OCPHはEG市場で注目すべき配当金を支払っていないため、支払額が増加しているかどうかを確認する必要はありません。配当利回り対市場October PharmaE 配当利回り対市場OCPH 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (OCPH)0.7%市場下位25% (EG)1.2%市場トップ25% (EG)5.5%業界平均 (Pharmaceuticals)2.1%アナリスト予想 (OCPH) (最長3年)n/a注目すべき配当: OCPHの配当金 ( 0.7% ) はEG市場の配当金支払者の下位 25% ( 1.16% ) と比べると目立ったものではありません。高配当: OCPHの配当金 ( 0.7% ) はEG市場の配当金支払者の上位 25% ( 5.52% ) と比較すると低いです。株主への利益配当収益カバレッジ: OCPHの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: OCPHの 現金配当性向 を計算して、配当金の支払いがキャッシュフローでカバーされているかどうかを判断するにはデータが不十分です。高配当企業の発掘7D1Y7D1Y7D1YEG 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/04 00:56終値2026/07/01 00:00収益2025/09/30年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋October Pharma S.A.E 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Upcoming Dividend • May 21Upcoming dividend of ج.م2.50 per shareEligible shareholders must have bought the stock before 28 May 2024. Payment date: 30 May 2024. The company last paid an ordinary dividend in April 2017. The average dividend yield among industry peers is 3.3%.
Upcoming Dividend • Apr 13Upcoming dividend of ج.م4.00 per shareEligible shareholders must have bought the stock before 20 April 2022. Payment date: 26 April 2022. Payout ratio is a comfortable 15% and this is well supported by cash flows. Trailing yield: 1.9%. Lower than top quartile of Egyptian dividend payers (11%). Lower than average of industry peers (4.0%).
Upcoming Dividend • Jun 02Inaugural dividend of ج.م3.00 per shareEligible shareholders must have bought the stock before 09 June 2021. Payment date: 13 June 2021. The company last paid an ordinary dividend in May 2018. The average dividend yield among industry peers is 4.2%.
New Risk • Jun 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.7x net interest cover). Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported September 2025 fiscal period end). Market cap is less than US$100m (ج.م4.32b market cap, or US$82.7m).
Board Change • May 20No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. No independent directors (9 non-independent directors). MD & Director Hesham Abdul Soliman was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
お知らせ • Apr 06October Pharma S.A.E, Annual General Meeting, Apr 27, 2026October Pharma S.A.E, Annual General Meeting, Apr 27, 2026, at 15:30 Egypt Standard Time. Location: cairo Egypt
Board Change • May 14No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. No independent directors (9 non-independent directors). Director Hesham Abdul Soliman was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
お知らせ • May 13October Pharma S.A.E, Annual General Meeting, May 31, 2025October Pharma S.A.E, Annual General Meeting, May 31, 2025, at 12:00 Egypt Standard Time. Location: cairo Egypt
Reported Earnings • Nov 16Third quarter 2024 earnings released: EPS: ج.م2.67 (vs ج.م4.09 in 3Q 2023)Third quarter 2024 results: EPS: ج.م2.67 (down from ج.م4.09 in 3Q 2023). Revenue: ج.م326.1m (up 24% from 3Q 2023). Net income: ج.م32.0m (down 35% from 3Q 2023). Profit margin: 9.8% (down from 19% in 3Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has increased by 23% per year, which means it is tracking significantly ahead of earnings growth.
New Risk • Sep 17New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 2.7% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (2.7% operating cash flow to total debt). Minor Risks Profit margins are more than 30% lower than last year (9.9% net profit margin). Market cap is less than US$100m (ج.م1.41b market cap, or US$29.1m).
Valuation Update With 7 Day Price Move • Sep 17Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ج.م117, the stock trades at a trailing P/E ratio of 9.3x. Average trailing P/E is 6x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 124% over the past three years.
Reported Earnings • May 30First quarter 2024 earnings released: EPS: ج.م3.52 (vs ج.م2.94 in 1Q 2023)First quarter 2024 results: EPS: ج.م3.52 (up from ج.م2.94 in 1Q 2023). Revenue: ج.م274.4m (up 29% from 1Q 2023). Net income: ج.م50.1m (up 42% from 1Q 2023). Profit margin: 18% (up from 17% in 1Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has increased by 26% per year, which means it is tracking significantly ahead of earnings growth.
Upcoming Dividend • May 21Upcoming dividend of ج.م2.50 per shareEligible shareholders must have bought the stock before 28 May 2024. Payment date: 30 May 2024. The company last paid an ordinary dividend in April 2017. The average dividend yield among industry peers is 3.3%.
Reported Earnings • Mar 16Full year 2023 earnings released: EPS: ج.م12.53 (vs ج.م9.48 in FY 2022)Full year 2023 results: EPS: ج.م12.53 (up from ج.م9.48 in FY 2022). Revenue: ج.م1.01b (up 39% from FY 2022). Net income: ج.م182.1m (up 39% from FY 2022). Profit margin: 18% (in line with FY 2022). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has increased by 26% per year, which means it is tracking significantly ahead of earnings growth.
New Risk • Oct 01New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (ج.م1.20b market cap, or US$38.8m).
Valuation Update With 7 Day Price Move • Dec 21Investor sentiment improved over the past weekAfter last week's 19% share price gain to ج.م95.30, the stock trades at a trailing P/E ratio of 9.5x. Average trailing P/E is 5x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 210% over the past three years.
Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 9 non-independent directors. Director Hesham Abdul Soliman was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 9 non-independent directors. Director Hesham Abdul Soliman was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Upcoming Dividend • Apr 13Upcoming dividend of ج.م4.00 per shareEligible shareholders must have bought the stock before 20 April 2022. Payment date: 26 April 2022. Payout ratio is a comfortable 15% and this is well supported by cash flows. Trailing yield: 1.9%. Lower than top quartile of Egyptian dividend payers (11%). Lower than average of industry peers (4.0%).
Reported Earnings • Jun 19First quarter 2021 earnings releasedThe company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: ج.م165.8m (up 38% from 1Q 2020). Net income: ج.م40.6m (up 402% from 1Q 2020). Profit margin: 25% (up from 6.7% in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth.
Upcoming Dividend • Jun 02Inaugural dividend of ج.م3.00 per shareEligible shareholders must have bought the stock before 09 June 2021. Payment date: 13 June 2021. The company last paid an ordinary dividend in May 2018. The average dividend yield among industry peers is 4.2%.